VK2735Viking Therapeutics

What is VK2735?Overview

VK2735 is an investigational dual GLP-1/GIP receptor agonist developed by Viking Therapeutics for the treatment of obesity and type 2 diabetes. In Phase 2 trials, VK2735 demonstrated 14.7% mean weight loss in just 13 weeks—one of the fastest rates of weight reduction observed for any obesity medication—with 88% of patients achieving at least 10% weight loss.^[1]

What makes VK2735 particularly noteworthy is its rapid onset of action and potential for once-monthly maintenance dosing. The drug's extended half-life (170-250 hours) enables weekly injections during active treatment, with clinical data suggesting most patients maintain their weight loss for weeks after their last dose—opening the door to less frequent maintenance injections once target weight is achieved.

• What It Is: Once-weekly subcutaneous injectable GLP-1/GIP dual receptor agonist. Same mechanism class as tirzepatide (Zepbound/Mounjaro). Currently in Phase 3 trials (VANQUISH program).
• Efficacy Data: Phase 2 VENTURE trial: 14.7% weight loss at 13 weeks (vs. 1.6% placebo). 88% achieved ≥10% weight loss. Phase 2 oral formulation: 12.2% at 13 weeks.^[1][2]
• Development Status: Phase 3 VANQUISH-1 enrollment completed November 2025 (~4,650 patients, 78 weeks). VANQUISH-2 (type 2 diabetes) enrolling through Q1 2026. FDA approval estimated 2028-2029.^[3]

Why VK2735 Matters: Viking Therapeutics is a small biotech company challenging pharmaceutical giants like Eli Lilly and Novo Nordisk in the lucrative obesity treatment market. VK2735's rapid weight loss kinetics and potential for monthly maintenance dosing could differentiate it from competitors if Phase 3 results confirm the Phase 2 promise.

For patients seeking alternatives to tirzepatide (Zepbound) or semaglutide (Wegovy), VK2735 represents a pipeline option that could offer similar dual-agonist efficacy with potentially more convenient dosing—though it won't be available until 2028 at the earliest.

How VK2735 WorksDual-Agonist Mechanism

VK2735 works by simultaneously activating two key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual-agonist approach targets complementary pathways to produce synergistic effects on appetite, metabolism, and weight loss.^[4]

GLP-1 Receptor Activation

The GLP-1 component of VK2735 mimics the gut hormone GLP-1, which is naturally released after eating:

• Appetite Suppression: Activates GLP-1 receptors in the hypothalamus to reduce hunger and increase satiety between meals.
• Gastric Slowing: Delays gastric emptying, prolonging feelings of fullness after eating and reducing meal sizes.
• Glucose Control: Stimulates insulin secretion when blood sugar is elevated and suppresses inappropriate glucagon release.

GIP Receptor Activation

The GIP component adds metabolic effects beyond GLP-1 alone:

• Enhanced Insulin Response: GIP is responsible for the majority of the "incretin effect"—the enhanced insulin response to oral vs. intravenous glucose.
• Adipose Tissue Effects: GIP receptors in fat tissue may influence lipid metabolism and fat storage.
• Synergy with GLP-1: Combined GLP-1/GIP activation produces greater weight loss than GLP-1 alone, as demonstrated by tirzepatide's superior efficacy over semaglutide.

Clinical EvidenceTrial Results

VK2735's development has progressed through Phase 1 and Phase 2 trials with consistently positive results, leading to the ongoing Phase 3 VANQUISH program.

Phase 1 Trial (2022-2023)

Design: 28-day study in healthy obese volunteers evaluating safety, tolerability, and early efficacy signals.^[4]

• Weight Loss: Up to 18 pounds (8.2 kg) from baseline in 28 days
• Half-Life: 170-250 hours confirmed (supports weekly dosing)
• Safety: Well-tolerated with expected GI side effects

Phase 2 VENTURE Trial (Subcutaneous) - 2023-2024

Design: 13-week, randomized, double-blind, placebo-controlled trial enrolling 176 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities.^[1]

Results (Week 13):

• VK2735 (highest dose): -14.7% mean weight loss from baseline
• Placebo-adjusted: -13.1% greater weight loss vs. placebo
• ≥10% Weight Loss: 88% of patients (vs. 4% placebo)
• Discontinuation Rate: 13% (balanced with placebo at 14%)

Weight Loss Durability: At ObesityWeek 2024, Viking reported that patients maintained the majority of their weight loss 4 weeks after their final dose (p<0.0001 vs. baseline). At 7 weeks post-treatment, over 80% of weight loss was maintained.^[5]

Phase 2 VENTURE-Oral Trial (Tablet) - 2025

Design: 13-week trial of once-daily oral VK2735 tablet formulation in patients with obesity.^[2]

Results (August 2025):

• Weight Loss: Up to 12.2% from baseline at 13 weeks
• Placebo-Adjusted: Up to 10.9% greater weight loss vs. placebo
• Safety: 99% of GI adverse events were mild or moderate
• Significance: Progressive weight loss with no plateau observed—suggesting potential for greater loss with longer treatment

Phase 3 VANQUISH Program (Ongoing)

Viking initiated the Phase 3 VANQUISH program in June 2025 to support FDA approval:^[3]

• VANQUISH-1 (Obesity): ~4,650 patients, 78-week treatment + 52-week extension. Doses: 7.5mg, 12.5mg, 17.5mg weekly. Enrollment completed November 2025.
• VANQUISH-2 (Type 2 Diabetes): ~1,100 patients with obesity/overweight and T2D. Enrollment expected to complete Q1 2026.

Safety and Side EffectsSafety Profile

VK2735's safety profile in Phase 2 trials was consistent with the GLP-1/GIP agonist class, featuring predominantly mild-to-moderate gastrointestinal adverse events that were transient and manageable. Importantly, the discontinuation rate was low and balanced with placebo.^[1]

Common Side Effects (Phase 2 VENTURE)

• Nausea: 43% (mostly mild—32% mild, remainder moderate)
• Vomiting: 18% of patients
• GI Event Pattern: Decreased upon repeat dosing (improved over time)
• Overall AE Severity: 92% of adverse events were mild or moderate

Tolerability Indicators

• Discontinuation Rate: 13% (VK2735) vs. 14% (placebo)—no excess discontinuation due to treatment
• Serious Adverse Events: 1 case of dehydration (drug-related)
• No Deaths: No fatal adverse events reported in Phase 2

Oral Formulation Safety (VENTURE-Oral)

The oral tablet showed an even more favorable GI profile:^[2]

• Nausea: 14-32% (lower than injectable)
• Vomiting: 0-4% of subjects
• Severity: 99% of GI AEs mild/moderate; 90% were mild
• No Serious AEs: No serious adverse events reported

Path to FDA ApprovalApproval Timeline

Current Status: Phase 3 VANQUISH-1 enrollment completed November 2025. The 78-week treatment period means results are expected in late 2027, with FDA filing to follow.

Current AccessClinical Trials

VK2735 is not yet FDA-approved and is only accessible through clinical trial participation. The VANQUISH program is actively enrolling:

Note: Viking Therapeutics is a smaller company than Eli Lilly or Novo Nordisk, so trial sites may be more limited. Check trial listings carefully for locations near you.

Insurance Coverage OutlookCoverage Outlook

VK2735 is not yet FDA-approved and therefore not covered by any insurance plans. Post-approval coverage will depend on FDA labeling, pricing strategy, and payer negotiations.

Key Coverage Considerations

• Competitive Landscape: VK2735 will enter a market with established competitors (Zepbound, Wegovy). Payers may require step therapy through existing drugs first.
• Viking's Size: As a small biotech, Viking may have less negotiating power with payers compared to Eli Lilly or Novo Nordisk.
• Potential Advantages: If Phase 3 confirms rapid weight loss kinetics and monthly maintenance potential, VK2735 could differentiate on convenience.
• Type 2 Diabetes Indication: If approved for T2D (VANQUISH-2), Medicare Part D coverage becomes possible.

Realistic Outlook: Coverage will likely be challenging initially. Expect prior authorization requirements, step therapy mandates, and limited formulary placement. Patient assistance programs will be critical for access.